An evaluation of  75 Se selenomethionine scanning as a test of pancreatic function compared with the secretin-pancreozymin test.
The uptake of (75)Se Selenomethionine by the pancreas has been evaluated in 102 patients and compared with the secretin-pancreozymin test of pancreatic function. In groups of patients with chronic pancreatitis and cancer of the pancreas abnormal scans closely parallel the diminished exocrine secretion, especially bicarbonate output, following a submaximal dose of secretin. Thirty per cent of the group with no pancreatic abnormality have abnormal scans, though the secretinpancreozymin test is normal. Though a normal scan excludes the presence of chronic pancreatitis and cancer of the pancreas with a probability greater than 90%, an abnormal scan is found so frequently in normal subjects that it does not provide a reliable index of impaired pancreatic function.
D001639:Bicarbonates / Q000378:metabolism; D002446:Celiac Disease / Q000503:physiopathology; D002766:Cholecystokinin; D002908:Chronic Disease; D006801:Humans; D007565:Jaundice / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000503:physiopathology; D008105:Liver Cirrhosis, Biliary / Q000503:physiopathology; D008715:Methionine; D010179:Pancreas / Q000502:physiology / Q000503:physiopathology*; D010190:Pancreatic Neoplasms / Q000503:physiopathology; D010195:Pancreatitis / Q000503:physiopathology; D011877:Radionuclide Imaging; D012633:Secretin / Q000494:pharmacology; D012643:Selenium
D001639:Bicarbonates; D012633:Secretin; D002766:Cholecystokinin; D008715:Methionine; D012643:Selenium